Russell Investments Group Ltd. Raises Stock Position in Boston Scientific Corporation $BSX

Russell Investments Group Ltd. increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 17.6% in the 4th quarter, HoldingsChannel reports. The fund owned 1,945,575 shares of the medical equipment provider’s stock after acquiring an additional 291,108 shares during the period. Russell Investments Group Ltd.’s holdings in Boston Scientific were worth $185,677,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Lombard Odier Asset Management Europe Ltd acquired a new stake in Boston Scientific in the fourth quarter valued at approximately $13,662,000. Clark Capital Management Group Inc. grew its holdings in Boston Scientific by 724.2% in the fourth quarter. Clark Capital Management Group Inc. now owns 77,731 shares of the medical equipment provider’s stock worth $7,412,000 after purchasing an additional 68,300 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of Boston Scientific during the fourth quarter worth $102,000. Fred Alger Management LLC lifted its holdings in shares of Boston Scientific by 11.2% during the 4th quarter. Fred Alger Management LLC now owns 1,096,675 shares of the medical equipment provider’s stock valued at $104,568,000 after purchasing an additional 110,728 shares during the last quarter. Finally, &PARTNERS lifted its holdings in shares of Boston Scientific by 12.4% during the 4th quarter. &PARTNERS now owns 84,946 shares of the medical equipment provider’s stock valued at $8,101,000 after purchasing an additional 9,354 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX opened at $46.92 on Wednesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The company’s fifty day moving average price is $55.74 and its 200-day moving average price is $74.02. Boston Scientific Corporation has a 1-year low of $45.99 and a 1-year high of $109.50. The firm has a market capitalization of $69.74 billion, a PE ratio of 19.63, a price-to-earnings-growth ratio of 0.89 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same quarter last year, the business posted $0.75 EPS. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific announced that its board has authorized a share buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director David C. Habiger purchased 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the acquisition, the director owned 13,878 shares in the company, valued at $776,057.76. This represents a 19.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Edward J. Ludwig purchased 3,580 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 9,800 shares of company stock worth $554,012 over the last three months. 0.34% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Canaccord Genuity Group dropped their target price on Boston Scientific from $71.00 to $70.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Wolfe Research cut Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Stifel Nicolaus set a $75.00 price target on Boston Scientific in a research note on Wednesday, May 27th. Finally, Piper Sandler restated an “overweight” rating and set a $65.00 price objective on shares of Boston Scientific in a report on Friday. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.08.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.